Skip to main content

Table 5 Multivariate Tobit regression models on Direct Costs (Medication, Tests)

From: Impact of IPDE-SQ personality disorders on the healthcare and societal costs of fibromyalgia patients: a cross-sectional study

 

Direct costs

Medication

Tests

 

No PD

PD

No PD

PD

No PD

PD

(Intercept)

583.4 (478.0, 692.9)

785.2 (643.2, 949.8)

98.9 (50.3, 186.1)

155.2 (100.7, 241.7)

125.2 (60.6, 204.1)

136.1 (90.1, 179.5)

Age

−3.1 (−14.8, 7.2)

−25.2 a (−40.9, −12.4)

−4.0 (−11.6, 1.5)

−5.1 (−12.9, 0.7)

0.6 (−6.2, 6.9)

−5.5 (−11.1, −0.8)

Years with diagnosis

2.4 (−6.9, 12.6)

4.1 (−15.5, 21.6)

3.2 (−1.6, 7.6)

4.6 (−3.3, 17.0)

−1.3 (−6.9, 4.8)

−0.8 (−8.3, 4.2)

FIQ

12.3 a (6.3, 20.2)

20.8 a (7.1, 39.0)

2.7 (−0.8, 9.0)

1.6 (−3.2, 5.6)

3.3 a (0.2, 6.6)

5.2 a (0.9, 12.7)

  1. Note: Transformed Tobit coefficients with bootstrapped 95 % CIs (aindicating statistically significant coefficients –alpha = 0.05-). Explanatory variables centred to the sample mean. Accordingly, Intercept approximates the cost of a “mean individual” (aged 55.22, with 14.2 years with diagnosis, and a FIQ score of 56.36). For clarity, significant results are in bold